Latest Pro Medicus (ASX:PME) News

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.

Pro Medicus Limited has announced an on-market buy-back program targeting up to 10% of its ordinary shares, aiming to return capital to shareholders without requiring approval.

A single biotech result reset expectations in minutes, while gold and critical minerals kept investors busy on deals, drilling and funding. The week’s biggest moves came from one trial being stopped, a miner losing altitude after heavy selling, and a U.S. tungsten stock hit hard on risk-off trading.

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.

Pro Medicus Limited’s U.S. subsidiary has locked in two significant 5-year contract renewals worth a combined minimum of A$40 million, reinforcing its position in the competitive medical imaging market.

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Pro Medicus has reported its strongest half-year performance yet, with revenue and profits surging alongside a wave of new multi-million dollar contracts and strategic AI investments. The healthcare IT leader is expanding its global footprint and cloud capabilities, setting the stage for sustained growth.

Pro Medicus Limited reported a robust half-year performance, with underlying profit after tax rising by approximately 30%, driven by significant new sales and strategic implementations. The company remains confident in its proprietary technology's resilience against AI disruption while expanding its market footprint.

Pro Medicus Limited has reported a stellar half-year performance with revenue up 28.4% and a surge in net profit, driven by major US contract wins and strategic investments.

Pro Medicus has disclosed a contained data breach involving unauthorized access to a single employee email inbox, with limited exposure of personal information from around 100 current and former employees.

Pro Medicus Limited’s U.S. subsidiary has landed a $25 million, seven-year contract to deploy its cloud-based Visage 7 Open Archive with BayCare, extending an existing partnership and marking a significant step in its North American growth.